Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps

被引：117

作者：

Beatty, Gregory L.

O'Hara, Mark

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[2] Univ Penn, Dept Med, Div Hematol Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

PHARMACOLOGY & THERAPEUTICS | 2016年 / 166卷

基金：

美国国家卫生研究院;

关键词：

CART cells; Chimeric antigen receptor; Solid malignancies; Tumor microenvironment; Cellular immunity; ANTITUMOR-ACTIVITY; IN-VIVO; PHASE-I; INDOLEAMINE 2,3-DIOXYGENASE; IMMUNE PRIVILEGE; CLINICAL-TRIAL; SAFETY SWITCH; GENE-THERAPY; IFN-GAMMA; CANCER;

D O I：

10.1016/j.pharmthera.2016.06.010

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Chimeric antigen receptor (CAR) T cell therapy has shown promise in CD19 expressing hematologic malignancies, but how to translate this success to solid malignancies remains elusive. Effective translation of CART cells to solid tumors will require an understanding of potential therapeutic barriers, including factors that regulate CART cells expansion, persistence, trafficking, and fate within tumors. Herein, we describe the current state of CART cells in solid tumors; define key barriers to CART cell efficacy and mechanisms underlying these barriers, outline potential avenues for overcoming these therapeutic obstacles, and discuss the future of translating CART cells for the treatment of patients with solid malignancies. (C) 2016 Elsevier Inc. All rights reserved.

引用

页码：30 / 39

页数：10

共 109 条

[1]

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma [J].

Ahmed, Nabil ;

Brawley, Vita S. ;

Hegde, Meenakshi ;

Robertson, Catherine ;

Ghazi, Alexia ;

Gerken, Claudia ;

Liu, Enli ;

Dakhova, Olga ;

Ashoori, Aidin ;

Corder, Amanda ;

Gray, Tara ;

Wu, Meng-Fen ;

Liu, Hao ;

Hicks, John ;

Rainusso, Nino ;

Dotti, Gianpietro ;

Mei, Zhuyong ;

Grilley, Bambi ;

Gee, Adrian ;

Rooney, Cliona M. ;

Brenner, Malcolm K. ;

Heslop, Helen E. ;

Wels, Winfried S. ;

Wang, Lisa L. ;

Anderson, Peter ;

Gottschalk, Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) :1688-+

[2]

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer [J].

Ali, Khaled ;

Soond, Dalya R. ;

Pineiro, Roberto ;

Hagemann, Thorsten ;

Pearce, Wayne ;

Lim, Ee Lyn ;

Bouabe, Hicham ;

Scudamore, Cheryl L. ;

Hancox, Timothy ;

Maecker, Heather ;

Friedman, Lori ;

Turner, Martin ;

Okkenhaug, Klaus ;

Vanhaesebroeck, Bart .

NATURE, 2014, 510 (7505) :407-+

[3]

Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia [J].

Barrett, David M. ;

Liu, Xiaojun ;

Jiang, Shuguang ;

June, Carl H. ;

Grupp, Stephan A. ;

Zhao, Yangbing .

HUMAN GENE THERAPY, 2013, 24 (08) :717-727

[4]

Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer [J].

Bayne, Lauren J. ;

Beatty, Gregory L. ;

Jhala, Nirag ;

Clark, Carolyn E. ;

Rhim, Andrew D. ;

Stanger, Ben Z. ;

Vonderheide, Robert H. .

CANCER CELL, 2012, 21 (06) :822-835

[5]

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages [J].

Beatty, Gregory L. ;

Winograd, Rafael ;

Evans, Rebecca A. ;

Long, Kristen B. ;

Luque, Santiago L. ;

Lee, Jae W. ;

Clendenin, Cynthia ;

Gladney, Whitney L. ;

Knoblock, Dawson M. ;

Guirnalda, Patrick D. ;

Vonderheide, Robert H. .

GASTROENTEROLOGY, 2015, 149 (01) :201-210

[6]

Immune Escape Mechanisms as a Guide for Cancer Immunotherapy [J].

Beatty, Gregory L. ;

Gladney, Whitney L. .

CLINICAL CANCER RESEARCH, 2015, 21 (04) :687-692

[7]

Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma [J].

Beatty, Gregory L. .

ONCOIMMUNOLOGY, 2014, 3 (04)

[8]

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies [J].

Beatty, Gregory L. ;

Haas, Andrew R. ;

Maus, Marcela V. ;

Torigian, Drew A. ;

Soulen, Michael C. ;

Plesa, Gabriela ;

Chew, Anne ;

Zhao, Yangbing ;

Levine, Bruce L. ;

Albelda, Steven M. ;

Kalos, Michael ;

June, Carl H. .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) :112-120

[9]

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma [J].

Beatty, Gregory L. ;

Torigian, Drew A. ;

Chiorean, E. Gabriela ;

Saboury, Babak ;

Brothers, Alex ;

Alavi, Abass ;

Troxel, Andrea B. ;

Sun, Weijing ;

Teitelbaum, Ursina R. ;

Vonderheide, Robert H. ;

O'Dwyer, Peter J. .

CLINICAL CANCER RESEARCH, 2013, 19 (22) :6286-6295

[10]

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].

Beatty, Gregory L. ;

Chiorean, Elena G. ;

Fishman, Matthew P. ;

Saboury, Babak ;

Teitelbaum, Ursina R. ;

Sun, Weijing ;

Huhn, Richard D. ;

Song, Wenru ;

Li, Dongguang ;

Sharp, Leslie L. ;

Torigian, Drew A. ;

O'Dwyer, Peter J. ;

Vonderheide, Robert H. .

SCIENCE, 2011, 331 (6024) :1612-1616

← 1 2 3 4 5 6 7 8 9 10 →